New evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response
We want to draw your attention to the latest publication of the King’s College London, in Cardiovascular Diabetology. The research team provides new evidence for the clinical utility of platelet microRNA biomarkers for monitoring treatment response in type-2 diabetics with cardiovascular disease.
“Aspirin, clopidogrel and prasugrelmonotherapy in patients with type2diabetesmellitus: a double-blindrandomisedcontrolledtrial of the effects on thromboticmarkers and microRNAlevels.” Parker WAE, Schulte C, Bawari T, et al.Cardiovasc Diabetol. 2020 Jan 7;19(1):3. doi: 10.1186/s12933-019-0981-3.